- Policy
- Expansion of # of members of the Committee to around 105
- by Lee, Tak-Sun Jun 22, 2023 05:43am
- The number of members of the Pharmaceutical Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service will be expanded from around 100 to around 105. It is a policy to strengthen the expertise in evaluating the adequacy of drug treatment benefits by increasing the number of experts recommended by pharmaceutical
- Policy
- New drug pre-registration - post-evaluation non-face-to-face
- by Lee, Jeong-Hwan Jun 22, 2023 05:41am
- The government plans to include discussions on the need to apply innovative insurance systems such as new drugs and new medical technology 'seondeungjae-postevaluation' to strengthen treatment coverage for severe diseases such as cancer in the '2nd National Health Insurance Comprehensive Plan' to be established in the second half of this year
- Policy
- MFDS cautious about strengthening regulations
- by Lee, Jeong-Hwan Jun 22, 2023 05:40am
- The Ministry of Food and Drug Safety explained that although the MFDS with the purpose of the legislation to strengthen regulations on drugs that have been conditionally approved for expedited marketing authorizations before completing Phase III clinical trials from the current guideline level to the Pharmaceutical Affairs Act level, its app
- Policy
- Imported orphan drug specimen storage standards
- by Lee, Hye-Kyung Jun 22, 2023 05:40am
- The Ministry of Food and Drug Safety (Minister Oh Yoo-gyeong) announces a legislative announcement on the 21st of the amendment to the 'Rules on Safety of Pharmaceuticals, Etc. and, comments are accepted until August 21st. The main contents of this revision are ▲ rationalization of sample storage standards for importers of imported orphan dr
- Policy
- 85% of the public requests more coverage for severe diseases
- by Lee, Jeong-Hwan Jun 21, 2023 05:52am
- A survey found that more than 8 of 10 Koreans are in favor of increasing health insurance spending on new health technologies and new drugs to treat severe diseases such as cancer and rare diseases. Also, over 80% of the respondents agreed that the proportion of new drugs in total health insurance pharmaceutical spending should be increas
- Policy
- Mandatory benefit for Erleada impact?
- by Lee, Tak-Sun Jun 20, 2023 05:36am
- As Erleada, a prostate cancer treatment, has received mandatory reimbursement since last April, attention is focusing on whether the co-payment ratio for Xtandi and Zytiga in the same class will be reduced. Currently, Erleada receives mandatory benefits with a co-payment of 5%, and Xtandi·Zytiga receives 30% screening benefits. The Cancer Di
- Policy
- Negotiations between Verquvo and Retevmo begin
- by Lee, Tak-Sun Jun 20, 2023 05:36am
- Retevmo, an anticancer drug with mutations in RET, and Verquvo, a treatment for chronic heart failure, have entered into drug price negotiations with the NHIS. It is said that negotiations are still underway for Cibinqo, which started negotiations on drug prices in March, and Onureg, which started negotiations with the company last month. The
- Policy
- Rationalization of expedited review of new pharmaceuticals
- by Lee, Hye-Kyung Jun 20, 2023 05:35am
- In the case of a new drug developed by a first-in-class pharmaceutical company, a priority review request can be made to the rapid review division of the Ministry of Food and Drug Safety. The Ministry of Food and Drug Safety recently prepared detailed procedures, such as the method of requesting designation from the Minister of Health and Welfar
- Policy
- 100 billion won more for new drug 500 billion won megafund
- by Lee, Hye-Kyung Jun 19, 2023 06:00am
- The government plans to create an additional fund of 100 billion won this year following the creation of a 500 billion won 'mega fund' last year to strengthen investment and export support for the pharmaceutical and bio industries. However, since a proper drug price valuation must necessarily accompany first-in-class development support, i
- Policy
- Awareness of Korean pharmaceuticals, ranked 7th out of 13
- by Lee, Hye-Kyung Jun 16, 2023 05:55am
- In an awareness survey conducted on overseas consumers in countries leading the world's bio-health industry, they ranked 7th out of 13 countries in the pharmaceutical sector, 7th out of 15 countries in the medical device sector, 3rd out of 12 countries in the cosmetics sector, and 3rd out of 12 countries in the medical service sector. It was ran
